Second-Generation Drug-Eluting Stents and the Continuous Need for Rapidly Available Real-World Data⁎⁎Editorials published in JACC: Cardiovascular Interventions reflect the views of the authors and do not necessarily represent the views of JACC: Cardiovascular Interventions or the American College of Cardiology.  by Mukherjee, Debabrata & Moliterno, David J.
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econd-Generation
rug-Eluting Stents and the
ontinuous Need for Rapidly
vailable Real-World Data*
ebabrata Mukherjee, MD, David J. Moliterno, MD
exington, Kentucky
rug-eluting stents (DES), by markedly reducing the need
or repeat target vessel revascularization (TVR) compared
ith bare-metal stents (BMS), have been so rapidly and
idely employed that use continues to far outpace data
egarding indications and outcomes. After the initial success
f first-generation DES (Cypher [Cordis Corporation,
ridgewater, New Jersey] sirolimus-eluting stent [SES] and
axus [Boston Scientific, Natick, Massachusetts] paclitaxel-
luting stent [PES]), many questions emerged regarding
heir long-term safety and effectiveness, particularly for
ff-label indications. So, too, questions continued whether
ES and SES provide comparable in-class outcomes. Before
See pages 1178, 1190, 1199, 1208, 1219, and 1227
hese questions could be clearly answered, 2 second-
eneration DES were approved by the U.S. Food and Drug
dministration (FDA): the Xience/Promus (Boston Scien-
ific) everolimus-eluting stent (EES) and the Endeavor
Medtronic, Minneapolis, Minnesota) zotarolimus-eluting
tent (ZES). The EES has theoretical advantages over
rst-generation DES, owing to its thin-strut design, re-
uced polymer layer, as well as use of a novel drug (1). The
ES is also a thin-strut cobalt-based alloy stent with a thin
phosphorylcholine) polymer layer and a new “limus” drug
2). Just as the long-term experience with the first-
eneration DES began to materialize, especially from
nique cohorts, the second-generation DES were tested
gainst them (mainly PES) in head-to-head comparisons.
Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
From the Gill Heart Institute and Division of Cardiovascular Medicine, University
f Kentucky, Lexington, Kentucky. Dr. Moliterno has received past honoraria forw
erving on the Data and Safety Monitoring Committees for Boston Scientific and
uidant/Abbott, manufacturers of drug-eluting stents.The large randomized SPIRIT III (Clinical Evaluation of
he Xience V Everolimus Eluting Coronary Stent System in
he Treatment of Patients with de novo Native Coronary
rtery Lesions) study demonstrated that EES resulted in
educed angiographic late loss, noninferior rates of target vessel
ailure, and fewer major adverse cardiac events (MACE) than
ES during 1-year follow-up (3). Two-year follow-up showed
hat patients treated with EES had a significantly improved
vent-free survival compared with PES-treated patients (4).
n the basis of favorable data and ease of deliverability, EES
uickly became a global market contender and captured more
han 50% of the U.S. market (5). The initial enthusiasm
egarding ZES was dampened by greater angiographic late-
oss compared with other DES as reported in the EN-
EAVOR II (Long-Term Clinical and Economic Analysis of
he Endeavor Drug-Eluting Stent Versus the Driver Bare
etal Stent: 4-Year Results from the Endeavor Zotarolimus-
luting Phosphorylcholine-Encapsulated Stent for Treatment
f Native Coronary Artery Lesions Trial) (6) and EN-
EAVOR IV (Randomized, Controlled Trial of the
edtronic Endeavor Drug [ABT-578] Eluting Coronary
tent System Versus the Taxus Paclitaxel-Eluting Coronary
tent System in De Novo Native Coronary Artery Lesions)
7) trials, although this did not translate into a higher early
ate of TVR. Gershlick et al. (8) pooled outcomes from the
rst several ZES clinical studies including 1,317 patients
nd reported that, despite varied baseline clinical and
ngiographic characteristics, treatment with the ZES was
ssociated with consistently low rates of TVR, stent throm-
osis, and overall MACE at 2-year follow-up.
Clinical outcome data from everyday practice were very
imited for both EES and ZES until recently. Before the
resent publication by Latib et al. (9), data considering the
ffectiveness of EES for complex lesions among unselected
atients were only available from the X-SEARCH (Xience
Stent Evaluated at Rotterdam Cardiac Hospital) registry
10). The X-SEARCH registry included 649 consecutive
atients who were treated exclusively with EES and com-
ared with historical control subjects. The results suggested
hat EES have safety similar to BMS and both first-
eneration DES, are more effective than BMS and PES,
nd are similarly effective as SES. In this issue of JACC:
ardiovascular Interventions, Latib et al. (9) report unre-
tricted EES implantation in an observational study of 345
atients. The EES were implanted predominantly for off-
abel indications (72%) and were associated with a relatively
ow rate of MACE (11%) and target lesion revascularization
8%) at a median follow-up of 1 year. This study provides
linically relevant data on the usefulness of EES in practice
ut has limitations, given its relatively small cohort size and
ingle-center experience. Another paper in this issue of
ACC: Cardiovascular Interventions provides large-scale per-
pective on the performance of ZES in real-world settings
ith the E-Five registry (A World-Wide Registry With
T
r
p
c
c
4
r
r
s
t
i
o
i
n
(
a
a
Z
d
s
w
t
Z
t
p
m
e
a
b
r
a
s
p
s
t
d
t
(
p
t
(
s
w
i
(
s
S
c
c
s
a
b
6
[
l
t
f
P
E
T
o
p
a
l
H
c
G
I
t
f
g
c
f
(
a
a
i
t
w
i
a
p
a
h
c
(
E
n
t
Z
E
E
S
1
t
D
q
e
t
o
d
t
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 1 2 , 2 0 0 9 Mukherjee and Moliterno
D E C E M B E R 2 0 0 9 : 1 2 3 6 – 9 Editorial Comment
1237he Endeavor Zotarolimus Eluting Coronary Stent) as
eported by Lotan et al. (11). The E-Five registry is a
rospective, nonrandomized, global registry including 188
enters and 8,314 patients undergoing percutaneous revas-
ularization with ZES. The 12-month MACE rates were
.3% and 8.6% for standard-use and extended-use patients,
espectively (p  0.001), suggesting a doubling of event
ates for off-label or extended use of ZES as compared with
tandard use (11).
Given that most interventionalists now have at least 4
ypes of DES available, the important question to be asked
s: “What should clinicians realistically expect in terms of
utcomes if second-generation DES were to be implanted
n unselected patients including those with complex coro-
ary lesions?” The reports by Latib et al. (9) and Lotan et al.
11) alone cannot completely answer this question but do
dd important perspective. As noted, MACE rates were
lmost double among patients with off-label use of EES or
ES compared with on-label use, although the differences
id not reach statistical significance in the Latib et al. (9)
tudy. Also the TVR rates were roughly 50% to 80% higher
ith off-label use. As such, the overall message to interven-
ionalists from these 2 reports should be that the EES and
ES are safe and effective when used for on-label indica-
ions, and somewhat higher event rates should be antici-
ated when they are used in more complex lesion subsets.
Larger datasets are needed from multicenter post-
arketing studies to define the magnitude of the increase in
vent rates with more widespread DES use and also to
scertain how second-generation DES perform relative to
oth of the first-generation DES regarding TVR. The FDA
ecommended to the manufacturers of DES that post-
pproval studies not be used to evaluate important unre-
olved safety and effectiveness issues from the premarket
hase. Instead, post-approval studies should: 1) assess whether
tent thrombosis rates plateau or continue to increase over
ime; 2) assess the incidence rate of cardiac death and myocar-
ial infarction (MI); 3) gather information on antiplatelet
herapy use; and 4) study routine clinical use of DES
12,13). Such delineation of outcomes in unselected
atients will eventually come from several ongoing mul-
icenter registries evaluating second-generation DES
Table 1).
Preliminary results from the SPIRIT V trial were pre-
ented at EURO PCR 2009 and suggested that outcomes
ith EES were comparable to or even better than those seen
n the earlier, randomized trials. The rates of reported TVR
2.8%) and stent thrombosis (0.66%) at 1 year were impres-
ively low (14). Similarly, preliminary results from the
PIRIT IV trial, which evaluated safety and efficacy of EES
ompared with PES for the treatment of more complex
oronary disease among 3,690 patients, were recently pre-
ented (15). Stone et al. (15) reported that there was a 2.6%
bsolute difference in the rate of 1-year target lesion failure detween the 2 stents, statistically favoring EES (4.2% vs.
.8%, hazard ratio [HR]: 0.62, 95% confidence interval
CI]: 0.46 to 0.82). Although the study was not powered to
ook at differences in stent thrombosis rates, the investiga-
ors found a difference between the 2 arms at 1 year: 0.29%
or EES versus 1.06% for PES (p  0.003). The COM-
ARE (A Prospective, Randomized Trial of Everolimus-
luting vs. Paclitaxel-Eluting Stents), also reported at
ranscatheter Cardiovascular Therapeutics 2009, assessed
utcomes between EES and PES among 1,800 unselected
atients (16). The primary composite end point of 1-year
ll-cause mortality, nonfatal MI, and TVR was significantly
ower in the EES arm compared with PES (6.2% vs. 9.1%,
R: 0.69, 95% CI: 0.50 to 0.95, p  0.023). Finally,
onsidering longer-term outcome from prior SPIRIT trials,
arg et al. (17), in this issue of JACC Cardiovascular
nterventions, report data from the SPIRIT II trial, which
ested EES versus PES among 300 patients. At 3-year
ollow-up, there was a trend for lower MACE in the EES
roup compared with PES (7.2% vs. 15.9%, p  0.053).
This issue of JACC: Cardiovascular Interventions also in-
ludes long-term clinical and economic analysis of the ZES
rom several ENDEAVOR trials, including ENDEAVOR II
18), III (19), and IV (20). The common message from these
nalyses is that ZES demonstrates comparable clinical efficacy
nd economic attractiveness to first-generation DES with
mproved safety (fewer occurrences of MI and very late stent
hrombosis). Again, the higher initial angiographic late-loss
ith ZES did not translate into subsequent higher TVR rates
n these studies. Together, this has the potential to make ZES
n attractive option compared with first-generation DES by
roviding lower or comparable medical costs and better safety
nd quality-adjusted survival. However, not all studies to date
ave reported similar safety and efficacy profiles for ZES when
ompared with first-generation DES. The SORT-OUT III
A Prospective Randomized Comparison of Zotarolimus-
luting and Sirolimus-Eluting Stents in Patients with Coro-
ary Artery Disease) trial reported significantly higher stent
hrombosis, MI, and target lesion revascularization rates with
ES than SES (21). Separately, the ZEST (Zotarolimus-
luting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-
luting Stent for Coronary Lesions) trial compared ZES,
ES, and PES and found no differences in death or in MI at
-year follow-up (22).
With these varied reports it seems intuitive that future
rials and prospective registries assessing next-generation
ES will need to be quite large to adequately answer
uestions regarding safety (primarily stent thrombosis) and
fficacy (primarily in reducing TVR), especially considering
he growing category of “extended use.” At the same time
ther factors known to affect outcome (e.g., potency and
uration of dual antiplatelet therapy) need to be prospec-
ively defined and controlled as best possible. In summary,
espite an initial lack of data from complex patient subsets
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1238Table. Ongoing Post-Marketing Studies of the EES and ZES
Study End Points Comments
EES
XIENCE V Everolimus-Eluting Coronary Stent System
India Post-Marketing Registry (XIENCE V India)
Principal Investigators:
Ashok Seth, MD
Tejas Patel, MD
● Stent thrombosis rates as deﬁned by
ARC [time frame: annually through
5 yrs]
● Composite end point of cardiac death
and MI [time frame: 1 yr]
Observational, prospective consecutively enrolled cohort study of 1,000
patients. The group will be monitored to evaluate continued safety
and effectiveness during commercial use in real-world settings. Follow-
up will extend for 5 yrs.
Estimated study completion: June 2013
SPIRIT V: A Clinical Evaluation of the XIENCE V
Everolimus Eluting Coronary Stent System in
the Treatment of Patients With de Novo
Coronary Artery Lesions
Principal Investigators:
Eberhard Grube, MD
Upendra Kaul, MD
● SPIRIT V Diabetic Study: in-stent late
loss [time frame: 270 days]
● SPIRIT V Registry: adjudicated compos-
ite rate of all death, MI, and TVR [time
frame: 30 days] [designated as safety
issue: yes]
The SPIRIT V consists of 2 concurrent studies, the Diabetic Study and the
Registry. The SPIRIT V Registry is a prospective, single arm, multi-
center registry evaluating performance of the XIENCE V in real-world
use. 2,700 patients will be enrolled in the SPIRIT V Registry. Follow-up
will extend for 5 yrs.
Estimated study completion: November 2013
Preliminary 1-yr results: May 2009
XIENCE V Everolimus Eluting Coronary Stent System
(EECSS) USA Post-Approval Study
Principal Investigators:
James Hermiller, MD
Mitch Krucoff, MD
● ARC deﬁned stent thrombosis [time
frame: annually through 5 yrs]
● Composite rate of cardiac death and
any MI [time frame: 1 yr]
Observational, prospective cohort study of 8,000 patients. This study will
evaluate XIENCE V performance in the real world and will include all
consecutively enrolled patients in the U.S. who consent to participate and
receive the XIENCE V. The clinical follow-up will extend for 5 yrs.
The Post-Approval Study (XIENCE V USA) follow-up will document
patient adherence and persistence with adjunctive antiplatelet drug
therapy at several time points throughout the study.
Estimated study completion: July 2013
ZES
RESOLUTE International Registry: Evaluation of the
Endeavor Resolute Zotarolimus-Eluting Stent
System in a ‘Real-World’ Patient Population
Principal Investigators:
Franz-Josef Neumann, MD
Petr Widimský, MD
Jorge A. Belardi, MD
● Composite end point of cardiac death
and MI (not clearly attributable to a
nontarget vessel) [time frame: 1 yr]
● ARC-deﬁned stent thrombosis [time
frame: 1 yr]
The registry intends to enroll 2,200 patients from a large number of
centers under commercial usage conditions, with the aim to reﬂect
“real-world” usage as much as possible.
Estimated study completion: April 2011
RESOLUTE-KOREA Registry—Registry to Evaluate
the Efﬁcacy of Zotarolimus-eluting Stent
Principal Investigators:
Hyo-Soo Kim, MD, PhD
● MACE (composite of cardiac death,
nonfatal MI, target lesion revascular-
ization) [time frame: 1 yr]
Approximately 4,000 patients derived from a population of patients
receiving percutaneous coronary intervention for ischemic heart
disease will be enrolled in the present registry.
Estimated study completion: January 2012
China Endeavor Registry: A Registry With The
Endeavor Zotarolimus Eluting Coronary Stent
in China
Principal Investigators:
Jiyan Chen, Professor
Yaling Han, Professor
Yong Huo, Professor
Weimin Wang, Professor
Bo Xu, Director
● MACE [time frame: 1 yr] Approximately 2,200 patients from 37 sites to document the acute and
mid-term safety and overall clinical performance of the ZES in a
“real-world” Chinese patient population requiring stent implantation
Estimated study completion: November 2009
PROTECT Continued Access Post Marketing
Surveillance Trial (PROTECT-CA)
Principal Investigators:
Judith L Jaeger, BA
● To evaluate overall stent thrombosis
rate of the ZES in a patient population
requiring stent implantation [time
frame: 3 yrs]
To expand safety information in patients treated with the ZES or next
generation model, a continued access (CA) study of 1,000 patients was
added to the PROTECT Trial. The amended study is “PROTECT
CONTINUED ACCESS”
Estimated study completion: December 2014
Long-Term Safety of Drug Eluting Stents in the
“Real World” (FReIburger STent Registry)
(FRIST)
Principal Investigators:
Thorsten Grumann, MD
● All-cause mortality (cardiac and non-
cardiac death). [time frame: 5 yrs]
● The composite of death and MI and
stent thrombosis. [time frame: 5 yrs]
● The occurrence of TVR, stroke, major
bleeding, sepsis and tumor [time
frame: 5 yrs]
The FRIST registry is designed to determine the long-term safety and
efﬁcacy of DES in a “real-world” patient population requiring stent
implantation. Sirolimus-eluting stents, paclitaxel-eluting stents, ZES,
and uncoated (bare-metal) stents will be implanted.
Estimated primary completion: May 2009
E-Five Registry: A World-Wide Registry With The
Endeavor Zotarolimus Eluting Coronary Stent
(E-Five Registry)
Principal Investigators:
Ian T Meredith, MD
Chaim Lotan, MD
Martin T Rothman, MD
● MACE [time frame: 1 yr] Designed to document the acute and mid-term safety and overall clinical
performance of the stent system in a “real-world” 8,000 patient
population requiring stent implantation.
Estimated study completion: December 2008
Xience/Promus (Boston Scientific).
ARC Academic Research Consortium; DES drug-eluting stent(s); EES everolimus-eluting stent(s); IFU instruction for use; MACEmajor adverse cardiac events; MImyocardial infarction; TVRtarget vessel revascularization; ZES zotarolimus-eluting stent(s).
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1239eceiving second-generation DES, there are now substantial
eassuring data, and new benchmarks are being set. In the
uture, it should be a goal to obtain and report clinical-
xperience data more rapidly so that, as new-generation
evices emerge, outcome provided by their predecessors will
lready be established and well-understood. New device
iscovery and development should not slow, but rather the
ccumulation, interpretation, and dissemination of our col-
ective real-world experience need to accelerate and be more
ystematic.
eprint requests and correspondence: Dr. Debabrata Mukher-
ee, Division of Cardiovascular Medicine, University of Kentucky,
00 South Limestone Street, 326 Wethington Building, Lexing-
on, Kentucky 40536-0200. E-mail: Mukherjee@uky.edu.
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